Definitions
503A vs 503B: what the two compounding pathways actually are
A 503A compounding pharmacy compounds a drug for one identified individual patient against a valid prescription order, while a 503B outsourcing facility elects to register with the FDA and may compound without patient-specific prescriptions. The trade-off is written into the statute: 503A compounding is exempt from federal current good manufacturing practice requirements, and 503B compounding is not.
What a 503A compounding pharmacy is
"503A" is shorthand for Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 353a. It is not a licence or a registration — it is a conditional exemption. The statute suspends three federal requirements for a compounded drug product, but only when specific conditions are met:
Sections 351(a)(2)(B), 352(f)(1), and 355 of this title shall not apply to a drug product if the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order
Those three provisions are, in order, current good manufacturing practice, the requirement that labelling bear adequate directions for use, and new drug approval. The compounding must be performed by a licensed pharmacist in a state-licensed pharmacy or a federal facility, or by a licensed physician.
The patient-specific condition is the whole design
The exemption attaches to the act of compounding for one identified patient, not to the pharmacy as an institution. A 503A pharmacy does not hold a status that travels with everything it makes.
Section 353a(a)(2) permits compounding "in limited quantities before the receipt of a valid prescription order" where there is an established history of valid orders within a prescriber–patient–pharmacist relationship. Even then, the anticipatory stock is dispensed against a patient-specific prescription when one arrives; the subsection changes the timing, not the requirement.
Section 353a(b)(1)(D) separately prohibits compounding, regularly or in inordinate amounts, drug products that are essentially copies of a commercially available drug product.
What a 503B outsourcing facility is
Section 503B, codified at 21 U.S.C. § 353b, created a category that did not previously exist. A facility elects to register with the FDA as an outsourcing facility. The statutory definition at § 353b(d)(4) describes a facility at one geographic location or address that is engaged in the compounding of sterile drugs, has elected to register, and complies with all of the requirements of the section.
Two clarifications in that definition do most of the practical work: an outsourcing facility is not required to be a licensed pharmacy, and it may or may not obtain prescriptions for identified individual patients. The second is what makes non-patient-specific office stock possible at the federal level.
What each pathway is exempt from
This is the comparison that matters, and it is the one most often stated backwards. The exemptions are not the same set.
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| Governing statute | 21 U.S.C. § 353a | 21 U.S.C. § 353b |
| Who compounds | Licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician | Compounded by or under the direct supervision of a licensed pharmacist; the facility need not be a licensed pharmacy |
| Federal registration | Not a registration mechanism — state licensure governs | Elects to register with FDA as an outsourcing facility |
| State credential where it ships | A state board licence, plus a non-resident licence in each state it ships into | FDA registration does not travel. In every state we have read from primary sources the facility must also hold that state's own credential, and in some of them it is issued by an agency other than the board of pharmacy |
| Patient-specific prescription | Required — the exemption applies only when compounded for an identified individual patient on receipt of a valid prescription order | Not required — may or may not obtain prescriptions for identified patients |
| New drug approval (§ 355) | Exempt | Exempt |
| Adequate directions for use (§ 352(f)(1)) | Exempt | Exempt |
| Current good manufacturing practice (§ 351(a)(2)(B)) | Exempt | Not exempt — cGMP applies |
| Drug supply chain security (§ 360eee–1) | Not among the exemptions listed in § 353a(a) | Exempt |
| Registration cycle | Not applicable | Annually, between October 1 and December 31 |
| Product reporting to FDA | Not applicable | On initial registration and semi-annually, in June and December: active ingredient, source, dosage form, units produced and NDC numbers |
| FDA inspection | — | Risk-based schedule under § 374, considering compliance history, recalls, inherent drug risk and shortage-list status |
Reading the table the right way
The single most useful line is current good manufacturing practice. A 503A pharmacy is exempt from cGMP and buys that exemption with the patient-specific prescription requirement. A 503B outsourcing facility gives up the patient-specific requirement and pays for it with cGMP compliance, FDA registration, semi-annual product reporting, and risk-based inspection.
Neither is a "better" or "higher grade" pathway in the abstract. They are two different bargains, and the one that fits depends on whether the medication is going to a named patient or into a cabinet.
Which bargain a given supplier has actually struck — the registration, the credential in your own state, the chapter version it works to — is a separate exercise from reading the statute, and the records that answer it are mostly public. The sequence is set out in how to vet a compounding pharmacy.
Quality standards sit on a separate axis from the pathway, and they arrive from somewhere else entirely: USP writes the compounding chapters, and a state board of pharmacy — or an accreditor, by contract — is what makes a named version of one binding. What each chapter actually covers is set out in the glossary: <795> for non-sterile preparations, <797> for sterile preparations and beyond-use dating, and <800> for handling hazardous drugs.
Which applies to a prescriber's order
When a prescriber writes for a named patient, the 503A pathway is the one in play, and the preparation is compounded against that prescription.
When a practice wants stock on the shelf to administer to whoever presents — no patient named at the time of ordering — the federal pathway is 503B, because § 353a's exemption is unavailable by its own terms.
That federal answer is only half of it. Whether a prescriber may hold compounded office stock at all is decided by state law, and the states reviewed in our state-by-state office-use guide reach materially different answers — from express prohibition to a non-sterile-only permission with a mandatory label legend. Several state rules also condition office use on "applicable federal law," which routes the question straight back to § 353a.
State law decides what the facility may do as well. In every state we have read from primary sources, an outsourcing facility must hold that state's own credential before it may ship office stock in, and in some of them the credential is issued by an agency other than the board of pharmacy. What each state requires, and what your own practice must hold on top of it, is set out per state in that guide and operationally in how to place an office-use order.
Two errors worth naming
"FDA-registered 503A pharmacy" is a category error. FDA registration is the 503B mechanism. A 503A pharmacy is licensed by a state board of pharmacy; § 353b(d)(4) is explicit that the outsourcing facility is the entity that elects to register, and that it need not be a licensed pharmacy at all.
Registration with FDA is not permission to ship into your state. Section 353b is an exemption from specified federal requirements. It preempts no state licensing scheme, and it regulates the facility rather than the facility's customer — which is why the receiving side is a question of state law everywhere. A facility that satisfies § 353b in full and holds no credential in the destination state is not compliant; it is federally clean and state-exposed.
"503B-grade" is not a quality claim you can make about a preparation. What § 353b actually requires is cGMP compliance, registration, reporting and inspection at the facility level. Describing an individual compounded preparation as safer or more effective on that basis is a claim the statute does not support, and this page makes no such claim.
Where each half of the bargain is worked out
Three questions follow from the comparison above and each has its own page, because each one decides something this page only frames.
The condition on the 503A side. The patient-specific requirement is what the whole exemption is built around, and the exception for compounding ahead of an order is narrower than it is usually read: does a compounded drug need a patient-specific prescription. The arrangement most often mistaken for office use is set out beside it at anticipatory compounding compared with office use.
What either pathway may compound at all. Separately from who may receive it, a preparation can be barred from both routes by the restriction on compounding a copy of a commercially available drug — a federal test that turns on the approved product and moves on FDA's schedule rather than a legislature's: essentially a copy of a commercially available drug.
Why neither route ends in approval. Both provisions work by exempting the preparation from the new-drug approval requirement, which is why no compounded drug is ever approved and why the phrase is a misbranding exposure rather than a marketing one: why a compounded drug is never FDA-approved.
If the question behind yours is which of these binds your own kind of practice, the audience pages are organised by exactly that at sourcing by practice type.
This page compares the two pathways. Three related distinctions sit at other levels — two transactions, two regulatory objects, and two kinds of entity — and each is drawn on its own page in the comparison index.
Each term used above is also defined on its own page, in the words of the rule or agency document that supplies the definition: 503A pharmacy, then 503B outsourcing facility, and the requirement that separates them at cGMP.